Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its position in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 38.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,609 shares of the medical instruments supplier's stock after purchasing an additional 17,450 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.16% of Mesa Laboratories worth $8,130,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the company. Geneva Capital Management LLC boosted its stake in shares of Mesa Laboratories by 2.0% in the third quarter. Geneva Capital Management LLC now owns 191,976 shares of the medical instruments supplier's stock worth $24,930,000 after acquiring an additional 3,732 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Mesa Laboratories by 7.1% during the second quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier's stock valued at $11,444,000 after buying an additional 8,722 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of Mesa Laboratories by 8.4% in the second quarter. Raymond James & Associates now owns 80,739 shares of the medical instruments supplier's stock worth $7,006,000 after buying an additional 6,283 shares in the last quarter. Principal Financial Group Inc. grew its stake in Mesa Laboratories by 21.8% during the third quarter. Principal Financial Group Inc. now owns 35,107 shares of the medical instruments supplier's stock valued at $4,559,000 after acquiring an additional 6,292 shares in the last quarter. Finally, Meros Investment Management LP bought a new stake in Mesa Laboratories in the 2nd quarter valued at $2,456,000. Institutional investors own 90.60% of the company's stock.

Analyst Ratings Changes

MLAB has been the subject of a number of research reports. StockNews.com lowered Mesa Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, November 13th. Evercore ISI increased their target price on Mesa Laboratories from $120.00 to $160.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Finally, Wells Fargo & Company started coverage on Mesa Laboratories in a research report on Tuesday, August 27th. They set an "underweight" rating and a $120.00 target price for the company.

Insider Buying and Selling at Mesa Laboratories

In other news, SVP Brian David Archbold sold 1,499 shares of the business's stock in a transaction on Friday, September 13th. The stock was sold at an average price of $125.00, for a total value of $187,375.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gary M. Owens sold 2,518 shares of the business's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the completion of the transaction, the chief executive officer now owns 45,888 shares of the company's stock, valued at $5,213,794.56. This represents a 5.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by corporate insiders.

Mesa Laboratories Trading Down 0.1 %

MLAB traded down $0.08 on Wednesday, reaching $128.78. 30,222 shares of the company traded hands, compared to its average volume of 41,213. Mesa Laboratories, Inc. has a one year low of $83.68 and a one year high of $141.17. The firm has a fifty day simple moving average of $120.06 and a two-hundred day simple moving average of $114.90. The company has a market cap of $699.28 million, a P/E ratio of -2.83 and a beta of 0.86. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 29th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Friday, November 29th. Mesa Laboratories's dividend payout ratio (DPR) is presently -1.40%.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.